News Channels

02 Sep 2021 Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial
01 Sep 2021 Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™ (6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
01 Sep 2021 Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection
01 Sep 2021 Entos Pharmaceuticals' COVID-19 DNA Vaccine Candidate Approved for Phase 2 Clinical Trial in South Africa
01 Sep 2021 Asher Bio Closes $108 Million Series B Financing
01 Sep 2021 Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy
01 Sep 2021 FDA Approves Updated Indication for Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer)
01 Sep 2021 SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
31 Aug 2021 HUYABIO Files an Investigational New Drug Application with the FDA for the Novel SHP2 Inhibitor HBI-2376
31 Aug 2021 HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India
31 Aug 2021 Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit
31 Aug 2021 Adaptive Phage Therapeutics Announces Licensing Agreement with the Walter Reed Army Institute of Research
31 Aug 2021 Endevica Bio Reports TCMCB07 Preserves Lean Body Mass in Preclinical Cancer Cachexia Study
31 Aug 2021 AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease
31 Aug 2021 Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
31 Aug 2021 Bayer starts Phase III clinical development program OASIS with Elinzanetant
31 Aug 2021 Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma
31 Aug 2021 Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma
31 Aug 2021 Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of Ovarian Cancer CAR-T Immunotherapy
31 Aug 2021 Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up